Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Antisoma PLC (~292)

  Print      Mail a friend       Annual reports

Monday 26 July, 2004

Antisoma PLC

Research Update

Antisoma PLC
26 July 2004

     Antisoma gains exclusive rights to develop ATTACK agent BC1-IL12

London UK, 26 July 2004 -- Cancer drug development company Antisoma plc (LSE:
ASM) today announces that it has gained exclusive rights over the drug BC1-IL12
and will now accelerate the agent's development. This follows Antisoma's
acquisition of EMD Lexigen's half stake in the programme through the licensing
of technology as detailed below.

BC1-IL2, which will now be known as AS1409, is an ATTACK (Antitumour Therapy
with Targeting Antibodies and CytoKines) agent made using Lexigen's '
immunocytokine' technology to combine the cytokine IL12 with Antisoma's
tumour-targeting antibody BC1.

Antisoma will prepare AS1409 for clinical trials, building upon promising data
presented earlier this year at the American Association of Cancer Research
(AACR) meeting. The drug significantly reduced the growth of tumours in mice
carrying human colon, prostate and skin cancers. In a model of metastatic
(spreading) lung cancer, coverage of lung surfaces by tumour was 99% lower with
AS1409 than with a control.

Antisoma CEO Glyn Edwards said, 'Clinical trials have shown that IL12 used alone
has remarkable anti-cancer actions, but these are overshadowed by side effects.
AS1409 seeks to harness the power of IL12 by combining it with an antibody that
focuses its actions specifically on tumours. With promising preclinical data in
a variety of cancers we are keen to push this drug forward, and believe that it
will be a strong candidate for inclusion into our strategic alliance with 


Antisoma plc
Glyn Edwards, Chief Executive Officer                Tel: +44 (0)20 8799 8200

Financial Dynamics
Julia Phillips                                       Tel: +44 (0)20 7831 3113

De Facto Communications (mainland Europe)
Yvonne Alexander                                     Tel: +44 (0)20 7940 1000

Except for the historical information presented, certain matters discussed in
this statement are forward looking statements that are subject to a number of
risks and uncertainties that could cause actual results to differ materially
from results, performance or achievements expressed or implied by such
statements. These risks and uncertainties may be associated with product
discovery and development, including statements regarding the company's clinical
development programmes, the expected timing of clinical trials and regulatory
filings. Such statements are based on management's current expectations, but
actual results may differ materially.

Notes for Editors:

About the licensing deal

EMD Lexigen Research Center Corp is an affiliate of Merck KGaA, Darmstadt,
Germany.  Antisoma has acquired an exclusive, worldwide license to EMD Lexigen's
half-stake in the intellectual property arising from a jointly conducted
research programme and has licensed other technology from EMD Lexigen, EMD
Pharmaceuticals, Inc. and Biovation Ltd., also affiliates of Merck KGaA.

About Antisoma

Based in London, UK, Antisoma is a biopharmaceutical company that develops novel
products for the treatment of cancer. The Company fills its development pipeline
by acquiring promising new product candidates from internationally recognised
academic or cancer research institutions.  Its core activity is the preclinical
and clinical development of these drug candidates. Antisoma forms partnerships
with pharmaceutical companies to bring its products to market.  In November
2002, Antisoma formed a broad strategic alliance with Roche to develop and
commercialise products from Antisoma's pipeline. Please visit
for further information about Antisoma.

About EMD Lexigen Research Center

EMD Lexigen Research Center is a research-driven company focused on developing
new generations of therapies for cancer and other serious and life-threatening
diseases. EMD Lexigen is a subsidiary of Merck KGaA, Darmstadt, Germany. Its
research center, located in the Route 128 Biotech Corridor near Boston, Mass.,
is a hub for Merck KGaA's biological pharmaceutical research activities,
emphasizing advanced pharmaceutical platform technologies and novel drugs.

                      This information is provided by RNS
            The company news service from the London Stock Exchange                                

a d v e r t i s e m e n t